0I1B Stock Overview
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0I1B from our risk checks.
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.66 |
| 52 Week High | US$65.36 |
| 52 Week Low | US$43.31 |
| Beta | 2.07 |
| 1 Month Change | -7.22% |
| 3 Month Change | -5.37% |
| 1 Year Change | n/a |
| 3 Year Change | -57.40% |
| 5 Year Change | -37.89% |
| Change since IPO | -54.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I1B | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -1.0% | -1.1% | 2.2% |
| 1Y | n/a | -11.3% | 0.9% |
Return vs Industry: Insufficient data to determine how 0I1B performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0I1B performed against the UK Market.
Price Volatility
| 0I1B volatility | |
|---|---|
| 0I1B Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0I1B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0I1B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| 0I1B fundamental statistics | |
|---|---|
| Market cap | US$3.08b |
| Earnings (TTM) | -US$54.37m |
| Revenue (TTM) | US$1.71b |
1.8x
P/S Ratio-56.7x
P/E RatioIs 0I1B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I1B income statement (TTM) | |
|---|---|
| Revenue | US$1.71b |
| Cost of Revenue | US$713.67m |
| Gross Profit | US$993.53m |
| Other Expenses | US$1.05b |
| Earnings | -US$54.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 58.20% |
| Net Profit Margin | -3.18% |
| Debt/Equity Ratio | 13.6% |
How did 0I1B perform over the long term?
See historical performance and comparison